Results 221 to 230 of about 3,988,806 (312)

Immune pressure is key to understanding observed patterns of respiratory virus evolution in prolonged infections. [PDF]

Virus Evol
Coats A, Wang YR, Koelle K.
europepmc   +1 more source

Inference of Nipah virus evolution, 1999-2015. [PDF]

Virus Evol, 2021
Whitmer SLM, Lo MK, Sazzad HMS, Zufan S, Gurley ES, Sultana S, Amman B, Ladner JT, Rahman MZ, Doan S, Satter SM, Flora MS, Montgomery JM, Nichol ST, Spiropoulou CF, Klena JD.   +15 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Waning immunity drives respiratory virus evolution and reinfection. [PDF]

Evol Med Public Health
Bull JJ, Koelle K, Antia R.
europepmc   +1 more source

Virome diversity in small mammals from south China: Insights into virus evolution, transmission, and ecology. [PDF]

Virol Sin
Shi Y, Fang L, Li C, Li P, Liu J, Chen Y, Zhao Y, Li Z, Liu S, Ding Y, Zhou X, Jiang D, Shen J, Zhang Z, Lyu J, Pu R, Tan X, Yin J, Shi W, Cao G.   +19 more
europepmc   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Generative prediction of real-world prevalent SARS-CoV-2 mutation with in silico virus evolution. [PDF]

Brief Bioinform
Liu X, Nie Z, Si H, Shen X, Liu Y, Huang X, Dong T, Xu F, Ren Z, Zhou P, Chen J.   +10 more
europepmc   +1 more source

The Development of Rheumatoid Arthritis–Specific Ambulatory Care–Sensitive Conditions: Results of a Consensus Process

Arthritis Care &Research, EarlyView.
Objective Ambulatory care–sensitive conditions (ACSCs) serve as indicators of access, quality, and performance of the health system. This study aimed to determine rheumatoid arthritis (RA)‐specific ACSCs for use in the evaluation of care system access and quality.
Kara Irwin, Candace H. Feldman, Claire E. H. Barber, Gabriel Fabreau, Jake Jennings, Scott Patten, Cheryl Barnabe, Inflammatory Arthritis‐Specific ACSC Consensus Process Working Group   +7 more
wiley   +1 more source

Quantitatively analyzing the relationship between non-pharmaceutical interventions and the direction of virus evolution using a dynamic model. [PDF]

Front Public Health
Guo Z, Chen Y, Liu H, Xiao G, Yu D, Zhang Z, Yang Y, Yin Z, Zhang H.   +8 more
europepmc   +1 more source

Clinical Characteristics and Concordance of Anti‐MDA5 Antibodies: A Multicenter Australian Study

Arthritis Care &Research, EarlyView.
Objective In Australia, anti‐MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA‐positive anti‐MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti‐MDA5 antibodies. Methods Electronic records of a multisite cohort (patients
Syed B. Ali, Thomas Khoo, Keeran Shivakumar, Adam Caroll, Lauren Hender, Dimitra Beroukas, Kim Griggs, Celina Jin, Theo De Malmanche, Jessica Day, Gabor Major, Vidya Limaye   +11 more
wiley   +1 more source